Prevention and Treatment of NSAID Gastropathy

被引：25
作者：
Carla J. Gargallo
Carlos Sostres
Angel Lanas
机构：
[1] University Hospital Lozano Blesa,Service of Digestive Diseases
[2] Aragon Health Sciences Institute,undefined
[3] (IIS Aragón),undefined
[4] CIBERehd,undefined
[5] University of Zaragoza,undefined
来源：
Current Treatment Options in Gastroenterology | 2014年 / 12卷 / 4期
关键词：
NSAID gastropathy; Gastroprotection; Risk factors; Upper gastrointestinal bleeding; Treatment;
D O I：
10.1007/s11938-014-0029-4
中图分类号：
学科分类号：
摘要：
Nonsteroidal anti-inflammatory drug (NSAID) treatment will be necessary as part of our therapeutic armamentarium for many years to come. Therefore, safe prescription is mandatory in order to prevent adverse events. In the last two decades, new strategies and new drugs have been developed to reduce NSAID-associated upper gastrointestinal (GI) adverse events. Although the implementation of guidelines into clinical practice takes time, several studies have shown a recent and profound decrease in hospitalizations due to upper GI complications, which has been linked to widespread use of proton pump inhibitors (PPIs), better NSAID prescription, and decreased prevalence of Helicobacter pylori infection. This is encouraging.
引用
收藏
页码：398 / 413
页数：15
相关论文
共 394 条
[11]  
Jones R(2002)Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial Lancet 359 9-13
[12]  
Laine L(2006)Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin Clin Gastroenterol Hepatol 4 1082-1089
[13]  
Dubois RW(2014)Safe prescription recommendations for non steroidal anti-inflammatory drugs: consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG) Gastroenterol Hepatol 37 107-127
[14]  
Melmed GY(2009)Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of unsaid with gastroprotection and COX-2 inhibitors Drug Health Patient Saf 1 1-25
[15]  
Henning JM(2007)Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association Circulation 115 1634-1642
[16]  
Laine L(2005)Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects J Am Coll Cardiol 45 1295-1301
[17]  
Gabriel SE(2001)Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 1809-1817
[18]  
Jaakkimainen L(2001)Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants Thromb Haemost 86 563-568
[19]  
Bombardier C(2003)Concomitant coumarin-NSAID therapy and risk for bleeding Ann Pharmacother 37 12-16
[20]  
Huang JQ(1993)Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease Arch Intern Med 153 1665-1670
12345678910